Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter and Boehringer reported a Phase 3 failure.
Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.
The Biden administration has added popular weight loss and diabetes drugs, including Ozempic and Wegovy, to Medicare’s list ...
Wegovy, Ozempic added to list of drugs where the federal government will try winning discounts from manufacturers.
On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
The blockbuster diabetes and weight-loss drug semaglutide (Ozempic, Rybelsus, Wegovy) along with therapies for asthma, ...
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
The Centers for Medicare & Medicaid Services just announced 15 new drugs it wants to lower the cost for including popular, ...
The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback